Paper33765447
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.
Bosman M and 8 others. Lancet Gastroenterol Hepatol, 2021. Cited by 68 papers, by iCite.
Cite this record
ConductScience Library. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Papers, record 33765447. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33765447
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Abdominal Pain | Major topic |
| Irritable Bowel Syndrome | Major topic |
| Placebos | Major topic |
| Adult | |
| Case-Control Studies | |
| Europe | |
| Female | |
| Humans | |
| Male | |
| Placebo Effect | |
| Randomized Controlled Trials as Topic | |
| Severity of Illness Index | |
| United States | |
| United States Food and Drug Administration |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 33765446 | Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome. | https://conductscience.org/library/papers/33765446 |
Source PubMed
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42922994 | Investigating the contextual modulation of postoperative gastrointestinal motility: a methodological feasibility study combining a standardized intervention protocol with wireless motility capsule monitoring. | Front Psychol | 2026 | https://conductscience.org/library/papers/42922994 | PubMed |
| 42823420 | Irritable bowel syndrome. | Nat Rev Dis Primers | 2026 | https://conductscience.org/library/papers/42823420 | PubMed |
| 42682476 | Initiating multi-strain probiotics is associated with clinically meaningful symptom relief, better quality of life, and fewer treatment escalations in IBS-D/IBS-M: a Chinese real-world propensity-matched cohort study. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42682476 | PubMed |
| 42603224 | Biomarkers in Irritable Bowel Syndrome: Bridging Gut-Brain Mechanisms to Precision Care. | Curr Gastroenterol Rep | 2026 | https://conductscience.org/library/papers/42603224 | PubMed |
| 42558675 | Mapping research trends in irritable bowel syndrome and the gut microbiome: a cross-database bibliometric analysis. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42558675 | PubMed |
| 42211410 | Efficacy and safety of modified Gwakjeongtang (herbal medicine) for diarrhea-predominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. | Integr Med Res | 2026 | https://conductscience.org/library/papers/42211410 | PubMed |
| 42100776 | Acupuncture for irritable bowel syndrome comorbid with anxiety and depression: study protocol for a placebo run-in, randomized clinical trial. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42100776 | PubMed |
| 42094852 | Internet-delivered cognitive behavioral therapy and FODMAP diet for adults with irritable bowel syndrome: A four-arm randomized controlled trial. | Internet Interv | 2026 | https://conductscience.org/library/papers/42094852 | PubMed |
| 42017290 | Bifidobacterium bifidum G9-1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Trial (Binary STAR Study). | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42017290 | PubMed |
| 41922986 | Clinical and cost effectiveness of nurse led-structured management of diarrhoea predominant irritable bowel syndrome in primary care (Lincolnshire POACHER study); a randomised control trial. | BMC Prim Care | 2026 | https://conductscience.org/library/papers/41922986 | PubMed |
| 41827145 | Probiotics in Irritable Bowel Syndrome: An Umbrella Review of 27 Systematic Reviews on Methodological Quality and Certainty of Evidence. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827145 | PubMed |
| 41353332 | Chinese medicine (Tiao-Chang Ke-Min granules) placebo and nocebo effects for diarrhea-predominant irritable bowel syndrome: a study protocol for a randomized controlled trial based on a balanced experimental design. | BMC Complement Med Ther | 2025 | https://conductscience.org/library/papers/41353332 | PubMed |
| 41327057 | Outcome measures for irritable bowel syndrome: a scoping review. | BMC Med Res Methodol | 2025 | https://conductscience.org/library/papers/41327057 | PubMed |
| 41177820 | Clinical Characteristics and Outcomes of Rome IV Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea Prescribed With Ondansetron: A Real-World Study. | Neurogastroenterol Motil | 2025 | https://conductscience.org/library/papers/41177820 | PubMed |
| 41158898 | Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). | Cureus | 2025 | https://conductscience.org/library/papers/41158898 | PubMed |
| 41114660 | Unraveling nocebo effects in visceral pain: negative suggestion and adverse treatment experience uniquely shape visceral pain unpleasantness. | Pain | 2026 | https://conductscience.org/library/papers/41114660 | PubMed |
| 40692549 | Randomised controlled trial: nutritional supplements to relieve irritable bowel syndrome symptoms by targeting the gut microbiota. | J Nutr Sci | 2025 | https://conductscience.org/library/papers/40692549 | PubMed |
| 40431448 | Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable Bowel Syndrome Without Constipation: Results from a Double-Blind, Randomized, Placebo-Controlled Trial. | Nutrients | 2025 | https://conductscience.org/library/papers/40431448 | PubMed |
| 39867596 | Efficacy of vagus nerve stimulation in gastrointestinal disorders: a systematic review. | Gastroenterol Rep (Oxf) | 2025 | https://conductscience.org/library/papers/39867596 | PubMed |
| 39669195 | Herbal placebo response in clinical trials on irritable bowel syndrome: a systematic review and meta-analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39669195 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33765447
GET https://conductscience.org/api/papers/v1/33765447/cited_by?page=2